Implementing an Interdisciplinary Eating Disorder Screening and Treatment Program for Post-Bariatric Surgery Patients in Nova Scotia (TEAM-ED)

March 17, 2026 updated by: Aaron Keshen

The goal of this interventional study is to evaluate the Treatment and Evaluation for After Metabolic Surgery with Eating Disorders (TEAM-ED) program, which combines streamlined access to screening, diagnostic assessment, and treatment with an interdisciplinary team approach to treatment planning, for managing disordered eating in adults who have recently had weight loss surgery in Nova Scotia. The main question it aims to answer is 'can an interdisciplinary program for identifying and managing disordered eating after weight loss surgery be implemented in Nova Scotia?

This study will determine the feasibility and impact of the TEAM-ED program by assessing the following objectives:

  1. Reach (how effectively the program engages the target population [post-weight loss surgery patients])
  2. Effectiveness (the extent of the program's impact on key clinical outcomes related to disordered eating and weight management)
  3. Adoption (the extent to which the program is adopted and accepted by clinicians)
  4. Implementation (how consistent program delivery is and factors impacting consistent delivery)

Participants will complete a disordered eating screening questionnaire online every 3 months after weight loss surgery until they reach 18-months post-surgery. Participants found to have disordered eating will be referred to the Nova Scotia Provincial Eating Disorder Service (NSEDPS) for standard disordered eating treatment (brief cognitive behavioral therapy [CBT-T]) plus treatment plan oversight by both weight loss surgery and eating disorder specialists. Standard outcome measures will be collected at baseline, during eating disorder treatment, post-treatment, and at follow-ups. Participants may also be asked to do a one-on-one research interview about their experiences with the program.

Study Overview

Status

Recruiting

Conditions

Intervention / Treatment

Study Type

Interventional

Enrollment (Estimated)

250

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Locations

  • Canada
    • Nova Scotia
      • Halifax, Nova Scotia, Canada, B3H 2E2
        • Recruiting
        • Abbie J Lane Memorial Building, QEII Health Sciences Centre, Nova Scotia Health Authority
        • Contact:

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

  • ≥19 years old
  • Between 3- and 18-months post-weight loss surgery.
  • Able to complete English computer-based self-report questionnaires (with adequate accommodation, if necessary).

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Health Services Research
  • Allocation: N/A
  • Interventional Model: Single Group Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: TEAM-ED Program
Behavioral: Treatment and Evaluation for After Metabolic Surgery with Eating Disorders (TEAM-ED) Program
A program that combines a) streamlined access to screening, diagnostic assessment, and treatment (brief cognitive behaviour therapy [CBT-T]), b) an interdisciplinary team approach to treatment planning, for managing disordered eating in patients post-weight loss surgery.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Screening Engagement Rate
Time Frame: From the post-weight loss surgery timepoint when a participant is first enrolled in the screening procedure (3-, 6-, 9-, 12-, 15-, or 18-months) until 18-months post-surgery or until they screen positive for disordered eating.
Percentage of eligible patients (i.e., post-weight loss patients who are enrolled in the screening procedure) who complete the disordered eating screening measure (i.e., Loss of Control Over Eating Scale [LOCES]) at each timepoint (3-, 6-, 9-, 12-, 15-, and 18-month). To be calculated with the equation: [Actual # of LOCES completed at a timepoint] / [Total # of eligible patients who could have completed LOCES at that timepoint]
From the post-weight loss surgery timepoint when a participant is first enrolled in the screening procedure (3-, 6-, 9-, 12-, 15-, or 18-months) until 18-months post-surgery or until they screen positive for disordered eating.

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Proportion of eligible patients who undergo a disordered eating diagnostic interview.
Time Frame: From the post-weight loss surgery timepoint when a participant is first enrolled in the screening procedure (3-, 6-, 9-, 12-, 15-, or 18-months) until they screen positive for disordered eating.
Proportion of eligible patients (i.e., those who screen positive for disordered eating) who complete a disordered eating diagnostic interview led by a clinician using the Eating Disorder Examination - Bariatric Surgery Version (EDE-BSV).
From the post-weight loss surgery timepoint when a participant is first enrolled in the screening procedure (3-, 6-, 9-, 12-, 15-, or 18-months) until they screen positive for disordered eating.
Proportion of eligible patients who are diagnosed with disordered eating.
Time Frame: From the post-weight loss surgery timepoint when a participant is first enrolled in the screening procedure (3-, 6-, 9-, 12-, 15-, or 18-months) until they screen positive for disordered eating.
Proportion of eligible patients (i.e., those in the screening procedure who screen positive then attend a disordered eating diagnostic interview) who are diagnosed with disordered eating by the clinician conducting the interview based on the results of that assessment.
From the post-weight loss surgery timepoint when a participant is first enrolled in the screening procedure (3-, 6-, 9-, 12-, 15-, or 18-months) until they screen positive for disordered eating.
Change in disordered eating psychopathology severity from baseline to Week 4.
Time Frame: From baseline to Week 4.
Patients in TEAM-ED treatment will complete the Eating Disorder Examination Questionnaire (EDE-Q) at baseline, Week 4, post-treatment (Week 10), 1-month follow-up, and 3-month follow-up. EDE-Q global scores range from 0-6, with higher scores indicating increased severity of eating disorder psychopathology.
From baseline to Week 4.
Change in disordered eating psychopathology severity from baseline to post-treatment (Week 10).
Time Frame: From baseline to post-treatment (Week 10).
Patients in TEAM-ED treatment will complete the Eating Disorder Examination Questionnaire (EDE-Q) at baseline, Week 4, post-treatment (Week 10), 1-month follow-up, and 3-month follow-up. EDE-Q global scores range from 0-6, with higher scores indicating increased severity of eating disorder psychopathology.
From baseline to post-treatment (Week 10).
Change in disordered eating psychopathology severity from baseline to 1-month follow-up.
Time Frame: From baseline to 1-month follow-up (i.e., 1 month after Week 10).
Patients in TEAM-ED treatment will complete the Eating Disorder Examination Questionnaire (EDE-Q) at baseline, Week 4, post-treatment (Week 10), 1-month follow-up, and 3-month follow-up. EDE-Q global scores range from 0-6, with higher scores indicating increased severity of eating disorder psychopathology.
From baseline to 1-month follow-up (i.e., 1 month after Week 10).
Change in disordered eating psychopathology severity from baseline to 3-month follow-up.
Time Frame: From baseline to 3-month follow-up (i.e., 3 months after Week 10).
Patients in TEAM-ED treatment will complete the Eating Disorder Examination Questionnaire (EDE-Q) at baseline, Week 4, post-treatment (Week 10), 1-month follow-up, and 3-month follow-up. EDE-Q global scores range from 0-6, with higher scores indicating increased severity of eating disorder psychopathology.
From baseline to 3-month follow-up (i.e., 3 months after Week 10).
Change in anxiety symptom severity from baseline to Week 4.
Time Frame: From baseline to Week 4.
Patients in TEAM-ED treatment will complete the Generalized Anxiety Disorder Scale (GAD-7) at baseline, Week 4, post-treatment (Week 10), 1-month follow-up, and 3-month follow-up. GAD-7 total scores range from 0 to 21, with higher scores indicating greater severity of generalized anxiety symptoms.
From baseline to Week 4.
Change in anxiety symptom severity from baseline to post-treatment (Week 10).
Time Frame: From baseline to post-treatment (Week 10).
Patients in TEAM-ED treatment will complete the Generalized Anxiety Disorder Scale (GAD-7) at baseline, Week 4, post-treatment (Week 10), 1-month follow-up, and 3-month follow-up. GAD-7 total scores range from 0 to 21, with higher scores indicating greater severity of generalized anxiety symptoms.
From baseline to post-treatment (Week 10).
Change in anxiety symptom severity from baseline to 1-month follow-up.
Time Frame: From baseline to 1-month follow-up (i.e., 1 month after Week 10).
Patients in TEAM-ED treatment will complete the Generalized Anxiety Disorder Scale (GAD-7) at baseline, Week 4, post-treatment (Week 10), 1-month follow-up, and 3-month follow-up. GAD-7 total scores range from 0 to 21, with higher scores indicating greater severity of generalized anxiety symptoms.
From baseline to 1-month follow-up (i.e., 1 month after Week 10).
Change in anxiety symptom severity from baseline to 3-month follow-up.
Time Frame: From baseline to 3-month follow-up (i.e., 3 months after Week 10).
Patients in TEAM-ED treatment will complete the Generalized Anxiety Disorder Scale (GAD-7) at baseline, Week 4, post-treatment (Week 10), 1-month follow-up, and 3-month follow-up. GAD-7 total scores range from 0 to 21, with higher scores indicating greater severity of generalized anxiety symptoms.
From baseline to 3-month follow-up (i.e., 3 months after Week 10).
Change in depression symptom severity from baseline to Week 4.
Time Frame: From baseline to Week 4.
Patients in TEAM-ED treatment will complete the Patient Health Questionnaire (PHQ-9) at baseline, Week 4, post-treatment (Week 10), 1-month follow-up, and 3-month follow-up. PHQ-9 total scores range from 0 to 27, with higher scores indicating greater severity of depressive symptoms.
From baseline to Week 4.
Change in depression symptom severity from baseline to post-treatment (Week 10).
Time Frame: From baseline to post-treatment (Week 10).
Patients in TEAM-ED treatment will complete the Patient Health Questionnaire (PHQ-9) at baseline, Week 4, post-treatment (Week 10), 1-month follow-up, and 3-month follow-up. PHQ-9 total scores range from 0 to 27, with higher scores indicating greater severity of depressive symptoms.
From baseline to post-treatment (Week 10).
Change in depression symptom severity from baseline to 1-month follow-up.
Time Frame: From baseline to 1-month follow-up (i.e., 1 month after Week 10).
Patients in TEAM-ED treatment will complete the Patient Health Questionnaire (PHQ-9) at baseline, Week 4, post-treatment (Week 10), 1-month follow-up, and 3-month follow-up. PHQ-9 total scores range from 0 to 27, with higher scores indicating greater severity of depressive symptoms.
From baseline to 1-month follow-up (i.e., 1 month after Week 10).
Change in depression symptom severity from baseline to 3-month follow-up.
Time Frame: From baseline to 3-month follow-up (i.e., 3 months after Week 10).
Patients in TEAM-ED treatment will complete the Patient Health Questionnaire (PHQ-9) at baseline, Week 4, post-treatment (Week 10), 1-month follow-up, and 3-month follow-up. PHQ-9 total scores range from 0 to 27, with higher scores indicating greater severity of depressive symptoms.
From baseline to 3-month follow-up (i.e., 3 months after Week 10).
Change in psychosocial impairment from baseline to Week 4.
Time Frame: From baseline to Week 4.
Patients in TEAM-ED treatment will complete the Clinical Impairment Assessment (CIA) at baseline, Week 4, post-treatment (Week 10), 1-month follow-up, and 3-month follow-up. CIA total scores range from 0 to 48, with higher scores indicating greater psychosocial impairment due to eating disorder symptoms.
From baseline to Week 4.
Change in psychosocial impairment from baseline to post-treatment (Week 10).
Time Frame: From baseline to post-treatment (Week 10).
Patients in TEAM-ED treatment will complete the Clinical Impairment Assessment (CIA) at baseline, Week 4, post-treatment (Week 10), 1-month follow-up, and 3-month follow-up. CIA total scores range from 0 to 48, higher scores indicating greater psychosocial impairment due to eating disorder symptoms.
From baseline to post-treatment (Week 10).
Change in psychosocial impairment from baseline to 1-month follow-up.
Time Frame: From baseline to 1-month follow-up (i.e., 1 month after Week 10).
Patients in TEAM-ED treatment will complete the Clinical Impairment Assessment (CIA) at baseline, Week 4, post-treatment (Week 10), 1-month follow-up, and 3-month follow-up. CIA total scores range from 0 to 48, higher scores indicating greater psychosocial impairment due to eating disorder symptoms.
From baseline to 1-month follow-up (i.e., 1 month after Week 10).
Change in psychosocial impairment from baseline to 3-month follow-up.
Time Frame: From baseline to 3-month follow-up (i.e., 3 months after Week 10).
Patients in TEAM-ED treatment will complete the Clinical Impairment Assessment (CIA) at baseline, Week 4, post-treatment (Week 10), 1-month follow-up, and 3-month follow-up. CIA total scores range from 0 to 48, higher scores indicating greater psychosocial impairment due to eating disorder symptoms.
From baseline to 3-month follow-up (i.e., 3 months after Week 10).
Change in weight from baseline to Week 4.
Time Frame: From baseline to Week 4.
Patient weight as measured with a standard scale.
From baseline to Week 4.
Change in weight from baseline to post-treatment (Week 10).
Time Frame: From baseline to post-treatment (Week 10).
Patient weight as measured with a standard scale.
From baseline to post-treatment (Week 10).
Change in weight from baseline to 1-month follow-up.
Time Frame: From baseline to 1-month follow-up (i.e., 1 month after Week 10).
Patient weight as measured with a standard scale.
From baseline to 1-month follow-up (i.e., 1 month after Week 10).
Change in weight from baseline to 3-month follow-up.
Time Frame: From baseline to 3-month follow-up (i.e., 3 months after Week 10).
Patient weight as measured with a standard scale.
From baseline to 3-month follow-up (i.e., 3 months after Week 10).
Patient satisfaction with the TEAM-ED program.
Time Frame: At 3-month follow-up (i.e., 3 months after Week 10).
Patients in TEAM-ED treatment will participate in a semi-structured, one-on-one interview with a trained research assistant. The objectives of the interviews are to assess overall patient satisfaction with the program including strengths and weaknesses, perceived effectiveness, and areas requiring refinement.
At 3-month follow-up (i.e., 3 months after Week 10).
Screening Initiation Rate
Time Frame: From 3- to 18-months post-weight loss surgery.
Percentage of eligible patients (i.e., those who are 3- to 18-months post-weight loss surgery and receiving follow-up care at the study clinics) who initiate the screening procedure. This will be calculated using the equation: [number of patients who fill out their initial screening questionnaire] / [number of patients registered for follow-up care post-weight loss surgery at the study clinics]. *Screening questionnaire is the Loss of Control Over Eating Scale (LOCES).
From 3- to 18-months post-weight loss surgery.
Proportion of eligible patients who screen positive for loss of control eating.
Time Frame: From 3- to 18-months post-weight loss surgery.
Proportion of eligible patients (i.e., those enrolled in the screening procedure) who are identified via screening questionnaire as having loss of control eating. This will be calculated using the equation: [number of patients who screen positive for loss of control eating] / [number of patients enrolled in screening procedure]. *Screening questionnaire is the Loss of Control Over Eating Scale (LOCES).
From 3- to 18-months post-weight loss surgery.
Proportion of eligible patients who start disordered eating treatment.
Time Frame: From the post-weight loss surgery timepoint when a participant is first enrolled in the screening procedure (3-, 6-, 9-, 12-, 15-, or 18-months) until they screen positive for disordered eating.
Proportion of eligible patients (i.e., those diagnosed with disordered eating following diagnostic interview) who choose to start treatment for disordered eating.
From the post-weight loss surgery timepoint when a participant is first enrolled in the screening procedure (3-, 6-, 9-, 12-, 15-, or 18-months) until they screen positive for disordered eating.
Change in disordered eating symptom frequency from baseline to post-treatment.
Time Frame: From baseline to post-treatment (Week 10).
Patients in TEAM-ED treatment will complete the Eating Disorder Examination Questionnaire (EDE-Q) before and after the core sessions of brief cognitive behavior therapy (i.e., Week 10).
From baseline to post-treatment (Week 10).
Treatment Non-Response Rate
Time Frame: From baseline (Week 1) to post-treatment (Week 10).
Percentage of eligible patients (i.e., those who start disordered eating treatment) who are deemed as not progressing in therapy as expected (per the CBT-T treatment manual, as determined by the clinician conducting their sessions). To be calculated with the equation: [# of patients who start CBT-T] / [# of patients deemed 'non-responders' by their clinician.]
From baseline (Week 1) to post-treatment (Week 10).
Treatment Completion Rate
Time Frame: From baseline to 3-month follow-up (i.e., 3 months after Week 10)
Percentage of eligible patients (i.e., those who start disordered eating treatment) who complete the core treatment (i.e., 10 weekly sessions) and that complete core treatment plus follow-ups (i.e., 1- and 3-month sessions). To be calculated with the equation: [# of patients who start CBT-T] / [# of patients recorded as having completed their prescribed course of treatment by their clinician.]
From baseline to 3-month follow-up (i.e., 3 months after Week 10)
Program Dropout Rate
Time Frame: From recruitment initiation (Month 0) to recruitment end (Month 24).
Percentage of eligible patients (i.e., those who initiate the screening procedure) who dropout of the TEAM-ED program.
From recruitment initiation (Month 0) to recruitment end (Month 24).
Acceptability of the TEAM-ED program to clinicians.
Time Frame: At 12 and 18 months.
Clinicians engaged in the TEAM-ED program will be asked to complete a survey online at ~12 and 18 months into the study (i.e., following the start of recruitment). The objectives of these groups is to: Evaluate the interdisciplinary approach; Identify barriers and facilitators; Assess the perceived effectiveness; and Refine and optimize the model.
At 12 and 18 months.
Adjunctive Pharmacotherapy Initiation Rate
Time Frame: From baseline to 3-month follow-up.
Percentage of eligible patients (i.e., those who start disordered eating treatment) who initiate pharmacotherapy for related symptoms during their course of treatment. *This variable is observational - pharmacotherapy initiation is not being directed or controlled by the research protocol or research team.
From baseline to 3-month follow-up.

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Aaron Keshen

Collaborators

Queen Elizabeth II Health Sciences Centre Foundation

Investigators

  • Principal Investigator: Aaron Keshen, MD, Nova Scotia Health Authority

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

March 4, 2026

Primary Completion (Estimated)

May 1, 2027

Study Completion (Estimated)

May 1, 2027

Study Registration Dates

First Submitted

March 31, 2025

First Submitted That Met QC Criteria

March 31, 2025

First Posted (Actual)

April 6, 2025

Study Record Updates

Last Update Posted (Actual)

March 19, 2026

Last Update Submitted That Met QC Criteria

March 17, 2026

Last Verified

January 1, 2026

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • TEAM-ED

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

product manufactured in and exported from the U.S.

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Disordered Eating Behaviors

Clinical Trials on Treatment and Evaluation for After Metabolic Surgery with Eating Disorders (TEAM-ED) Program

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Serbia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe